secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001493152-24-014559
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 3.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026
--------------------------------------------------------------------------------

- Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.
- Net proceeds estimated at ~$9.6M; total gross proceeds raised in 2024 now $17.2M from two placements.
- Issued 6,960,864 common shares, pre-funded warrant for 951,500 shares, Series A/B warrants for 7.9M and 3.96M shares.
- Proceeds for working capital, Phase III TIGeR-PaC trial in LAPC, and pipeline expansion into additional cancer indications.
- Company expects cash runway into 2026; second interim analysis for TIGeR-PaC estimated in late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/0001493152-24-014559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224014559/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer